COMP <GO>
AMGN vs LLY // 10Y YIELD & FRED MACRO BETA
Amgen Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: AMGN 5
— LLY 10
▲ 10Y YIELD & FRED MACRO BETA LEADER: AMGN
LAST: $466.01 (+1.15%) • MKT CAP: $249.09B
macro-sensitivity
0.87
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMGN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMGN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.20% | 83.64% | -16.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.50% | 32.36% | -17.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 27.2x | 36.4x | -9.22 | AMGN | /valuation <GO> |
| Free Cash Flow Yield | 3.25% | 2.30% | +0.95 | AMGN | /fcf-yield <GO> |
| Operating Margin | 24.70% | 40.21% | -15.51 | LLY | /operating-margins <GO> |
| Net Profit Margin | 21.00% | 31.90% | -10.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 10.00% | 45.51% | -35.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.06% | 0.49% | +1.57 | AMGN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 9.29 | -5.46 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.77% | -0.27 | AMGN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.4 | 77.9 | -6.45 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.87 | 0.51 | +0.36 | AMGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.0x | 26.3x | +3.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $249.09B | $1.33T | -$1.09T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMGN REV | LLY REV | AMGN GROSS % | LLY GROSS % | AMGN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.75B | $65.18B | 67.2% | 83.0% | $8.10B | $16.81B |
| FY 2024 | $33.42B | $45.04B | 61.5% | 81.3% | $10.39B | $8.82B |
| FY 2023 | $28.19B | $34.12B | 44.0% | 79.3% | $7.20B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMGN // BETA 0.87
LLY // BETA 0.51